Format

Send to

Choose Destination
J Diabetes Investig. 2019 Jul 30. doi: 10.1111/jdi.13122. [Epub ahead of print]

Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study.

Author information

1
Division of Endocrinology and Metabolism, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
2
Division of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
3
Division of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

Abstract

Recent studies have shown that sodium-glucose cotransporter 2 inhibitors decrease the risk of heart failure in patients with type 2 diabetes. However, the precise mechanisms of action of these drugs are not well understood. In the present study, we evaluated the effect of treatment with tofogliflozin for 6 months on cardiac and vascular endothelial function in 26 patients with type 2 diabetes and heart diseases. Tofogliflozin treatment significantly decreased left ventricular end-diastolic dimensions and significantly increased flow-mediated vasodilation. Although E/e' did not significantly change after treatment, the decrease observed in the E/e' ratio was significantly correlated with the increase in acetoacetic acid and 3-hydroxybutyrate levels. These results suggest that sodium-glucose cotransporter 2 inhibitor might improve left ventricular dilatation and vascular endothelial function in patients with type 2 diabetes. Furthermore, it is suggested that the elevation of ketone bodies induced by sodium-glucose cotransporter 2 inhibitors might contribute to a protective effect in left ventricular diastolic dysfunction.

KEYWORDS:

Ketone body; Left ventricular diastolic function; Sodium-glucose cotransporter 2 inhibitor

PMID:
31361403
DOI:
10.1111/jdi.13122
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center